Chiusura precedente | 1,7000 |
Aperto | 1,6600 |
Denaro | 1,7100 x 900 |
Lettera | 1,7600 x 900 |
Min-Max giorno | 1,6500 - 2,0186 |
Intervallo di 52 settimane | 0,9200 - 3,7300 |
Volume | |
Media Volume | 4.572.704 |
Capitalizzazione | 428,452M |
Beta (5 anni mensile) | N/D |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,8000 |
Prossima data utili | 01 ago 2024 - 05 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 5,25 |
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment of heart failure Abstracts published in the Journal of Managed Care & Specialty Pharmacy (JMCP) THE WOODLANDS, Texas, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that findings from two studies on the cost-effectiveness and budget impact of INPEFA® (sotagliflozin) will be presented at the Academy of Managed
INPEFA recently approved by FDA for treatment of heart failure Express Scripts has determined that it will list INPEFA as a preferred product on Medicare national formularies on November 1, 2023 THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Express Scripts, the pharmacy benefits management (PBM) business of The Cigna Group's Evernorth, has determined that it will place INPEFA on its Premier Access and Premier Performance
Mr. Garner brings over 25 years of pharmaceutical industry experienceTHE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023. Mr. Garner has over 25 years of pharmaceutical industry experience, having started his career in the United Kingdom with roles of increasing seniority at Boehringer Ingelheim and Eli Lilly befo